Price
$111.79
Decreased by -0.41%
Dollar Volume
552.51 M
ADR%
1.74
Earnings Report Date (estimate)
Jan 25, 23 (N/A)
Market Cap.
194.91 B
Shares Float
1.73 B
Shares Outstanding
1.74 B
Beta
0.67
Price / Earnings
25.23
BPR
169.61
20D Range
108.87 115.17
50D Range
102.41 115.17
200D Range
92.83 122.66
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Jan 25, 23 1.03
Decreased by -21.97%
0.92
Increased by +11.96%
Oct 19, 22 1.15
Decreased by -17.86%
0.94
Increased by +22.34%
Jul 20, 22 1.43
Increased by +22.22%
1.13
Increased by +26.55%
Apr 20, 22 1.73
Increased by +31.06%
1.47
Increased by +17.69%
Jan 26, 22 1.32
Decreased by -8.97%
1.21
Increased by +9.09%
Oct 20, 21 1.40
Increased by +42.86%
0.94
Increased by +48.94%
Jul 22, 21 1.17
Increased by +105.26%
1.02
Increased by +14.71%
Apr 20, 21 1.32
Increased by +103.08%
1.27
Increased by +3.94%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 10.41 B
Decreased by -4.74%
1.44 B
Decreased by -31.67%
Increased by +13.78%
Decreased by -28.27%
Jun 30, 22 11.26 B
Increased by +10.11%
2.02 B
Increased by +69.72%
Increased by +17.93%
Increased by +54.13%
Mar 31, 22 11.89 B
Increased by +13.76%
2.45 B
Increased by +36.48%
Increased by +20.57%
Increased by +19.97%
Dec 31, 21 11.47 B
Increased by +7.17%
1.99 B
Decreased by -8.00%
Increased by +17.34%
Decreased by -14.15%
Sep 30, 21 10.93 B
Increased by +23.44%
2.10 B
Increased by +70.45%
Increased by +19.22%
Increased by +38.09%
Jun 30, 21 10.22 B
Increased by +39.51%
1.19 B
Increased by +121.42%
Increased by +11.63%
Increased by +58.71%
Mar 31, 21 10.46 B
Increased by +35.34%
1.79 B
Increased by +217.91%
Increased by +17.15%
Increased by +134.90%
Dec 31, 20 10.70 B
Increased by +28.71%
2.16 B
Increased by +106.10%
Increased by +20.20%
Increased by +60.13%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.